June 22 (Reuters) - Neurobo Pharmaceuticals Inc
:
* NEUROBO PHARMACEUTICALS' DA-1726 DEMONSTRATED SUPERIORITY IN WEIGHT LOSS, RETENTION OF LEAN BODY MASS, AND LIPID-LOWERING EFFECTS COMPARED TO SURVODUTIDE, IN PRE-CLINICAL MODELS
* NEUROBO PHARMACEUTICALS - DA-1726 ALSO EXHIBITED SUPERIOR GLUCOSE LOWERING COMPARED TO SURVODUTIDE
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.